Treatment of primary dysthymia with group cognitive therapy and pharmacotherapy: Clinical symptoms and functional impairments

American Journal of Psychiatry

Volumn 156, Issue 10, 1999, Pages 1608-1617

  Ravindran, Arun V ^a,b   Anisman, Hymie ^a   Merali, Zul ^a   Charbonneau, Yoland ^a   Telner, John ^a   Bialik, Robert J ^a   Wiens, Andrew ^a   Ellis, Jack ^a   Griffiths, Jenna ^a  

^a CARLETON UNIVERSITY   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SERTRALINE;

ADULT; ARTICLE; BEHAVIOR THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYSTHYMIA; FEMALE; FUNCTIONAL DISEASE; GROUP THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY;

EID: 0032820313     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.156.10.1608     Document Type: Article

References (75)

1. John JB, Wilcox C: A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. J Clin Psychiatry 1985; 46:26-31
2. Feighner JP, Boyer WF: Paroxetine in the treatment of depression: a comparison with imipramine and placebo. J Clin Psychiatry 1992; 53(Feb suppl):44-47
3. Ives JL, Heym J: Antidepressant agents. Annual Reports in Medicinal Chemistry 1989; 24:21-29
4. Andreasen NC, Black DW: Somatic treatments, in Introductory Textbook of Psychiatry, 2nd ed. Washington, DC, American Psychiatric Press, 1995, pp 655-700
5. Scott J: Cognitive therapy of affective disorders: a review. J Affect Disord 1996; 37:1-11
6. Andrews G: The evaluation of psychotherapy. Current Opinion in Psychiatry 1991; 4:379-383
7. Dobson K: A meta-analysis of the efficacy of cognitive therapy for depression. J Consult Clin Psychol 1989; 57:414-419
8. Teasdale JD, Segal Z, Williams JMG: How does cognitive therapy prevent depressive relapse and why should attentional control (mindfulness) training help? Behav Res Ther 1984; 33:25-39
9. Roth D, Bielski D, Jones M, Parker W, Osborn G: A comparison of self-control therapy and combined self-control therapy and antidepressant medication in the treatment of depression. Behavior Therapy 1982; 13:133-144
10. Murphy GE, Simons AD, Wetzel RD, Lustman PJ: Cognitive therapy and pharmacotherapy singly and together in the treatment of depression. Arch Gen Psychiatry 1984; 41:33-41
11. Beck AT, Hollon SD, Young JE, Bedrosian RC, Budenz D: Treatment of depression with cognitive therapy and amitriptyline. Arch Gen Psychiatry 1985; 42:142-148
12. Depression in Primary Care, vol 2: Treatment of Major Depression: DHHS Publication AHCPR 93-0551. Rockville, Md, Agency for Health Care Policy and Research, Depression Guideline Panel, 1993
13. Wexler BE, Cicchetti DV: The outpatient treatment of depression: implications of outcome research for clinical practice. J Nerv Mental Dis 1992; 180:277-286
14. Evans M, Hollon S, DeRubeis R, Piasecki J, Grove W, Garvey M, Tuason V: Differential relapse following cognitive therapy and pharmacotherapy of depression. Arch Gen Psychiatry 1992; 49:802-808
15. Fava GA, Grandi S, Zielezny M, Rafanelli C, Canestrari R: Four-year outcome for cognitive behavioral treatment of residual symptoms in major depression. Am J Psychiatry 1996; 153:945-947
16. Scott MJ, Stradling SG: Group cognitive therapy for depression produces clinically significant reliable change in community-based settings. Behav Psychother 1990; 18:1-19
17. Stravynski A, Verreault R, Gaudettte G, Langlois R, Gagnier S, Larose M: The treatment of depression with group behavioral-cognitive therapy and imipramine. Can J Psychiatry 1994; 39:387-390
18. Manning DW, Frances AJ: Group psychotherapy and pharmacotherapy of depression, in Combined Pharmacotherapy and Psychotherapy for Depression. Edited by Manning DW, Frances AJ. Washington, DC, American Psychiatric Press, 1990, pp 67-111
19. Salvendy JT, Joffe R: Antidepressants in group psychotherapy. Int J Group Psychother 1991; 41:465-480
20. Rush AJ, Watkins JT: Group versus individual cognitive therapy: a pilot study. Cognitive Therapy Res 1981; 5:95-103
21. Wierzbecki M, Bartlett TS: The efficacy of group and individual cognitive therapy for mild depression. Cognitive Therapy Res 1987; 11:337-342
22. Covi L, Lipman S: Cognitive behavioral group psychotherapy combined with imipramine in major depression. Psychopharmacol Bull 1987; 23:173-176
23. Paykel ES: Psychological therapies. Acta Psychiatr Scand 1994; 89:35-41
24. Markowitz JC: Psychotherapy of dysthymia. Am J Psychiatry 1994; 151:1114-1121
25. Thase ME, Fava M, Halbreich U, Kocsis JH, Koran L, Davidson J, Rosenbaum J, Harrison W: A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Arch Gen Psychiatry 1996; 53: 777-784
26. Baldwin D, Rudge S, Thomas S: Dysthymia: options in pharmacotherapy. CNS Drugs 1995; 4:422-431
27. Akiskal HS: Towards a definition of dysthymia: boundaries with personality and mood disorders, in Dysthymic Disorders. Edited by Burton SW, Akiskal HS. London, Gaskell, 1990, pp 1-12
28. Millon T: Millon Clinical Multiaxial Inventory - II. Minneapolis, National Computer Services, 1987
29. Sheehan DV, Lecrubier Y, Sheehan KH, Amorin P, Janavs J, Weiller E, Herguerta T, Baker R, Dunbar GC: The Mini-International Neuropsychiatric Interview, (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59(Suppl 20): 22-33
30. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 1961; 4:561-571
31. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6:278-296
32. Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389
33. Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959; 32:50-55
34. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 218-222
35. Mason BJ, Kocsis JH, Leon AC, Thompson S, Frances AJ, Morgan RO, Parides MK: Measurement of severity and treatment response in dysthymia. Psychiatr Annals 1993; 23:625-631
36. Kanner AD, Coyne JC, Schaefer C, Lazarus RS: Comparison of two modes of stress measurement: daily hassles and uplifts versus major life events. J Behav Med 1981; 4:1-39
37. Ravicki DA, Turner R, Brown R, Martindale JJ: Batelle Quality of Life Scale. Qual Life Res 1992; 1:257-266
38. Beckham EE, Adams RL: Coping behavior in depression: report on a new scale. Behav Res Ther 1984; 22:71-75
39. Hollon SD, Shaw BF: Group cognitive therapy for depressed patients, in Cognitive Therapy of Depression. Edited by Beck AT, Rush AJ, Shaw BF, Emery G. New York, Guilford Press, 1979, pp 328-353
40. McCullough JP: Cognitive-behavioral analysis system of psychotherapy: an interactional treatment approach for dysthymic disorder. Psychiatry 1984; 47:234-250
41. Hellerstein DJ, Yanowitch P, Rosenthal J, Samstag LW, Maurer M, Kasch K, Burrows L, Poster M, Cantillon M, Winston A: A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia. Am J Psychiatry 1993; 150: 1169-1175
42. Friedman RA, Markowitz JC, Parides M, Kocsis JH: Acute response of social functioning in dysthymic patients with desipramine. J Affect Disord 1995; 34:85-88
43. Kocsis JH, Zisook S, Davidson J, Shelton R, Yorkers K, Hellerstein DJ, Rosenbaum J, Halbreich U: Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes. Am J Psychiatry 1997; 154:390-395
44. Marin DB, Kocsis JH, Frances AJ, Parides M: Desipramine for the treatment of "pure" dysthymia versus "double" depression. Am J Psychiatry 1994; 151:1079-1080
45. Stewart JW, McGrath PJ, Quitkin FM, Rabkin J, Harrison W, Wager S, Nunes S, Ocepek-Welikson K, Tricamo E: Chronic depression: response to placebo, imipramine, and phenelzine. J Clin Psychopharmacol 1993; 13:391-396
46. Versiani M, Nardi AE, Figueira IL, Stabl M: Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo. Acta Psychiatr Scand Suppl 1990; 360:24-28
47. Petursson H: Studies of reversible and selective inhibitors of monoamine oxidase A in dysthymia. Acta Psychiatr Scand Suppl 1995; 386:36-39
48. Vallejo J, Gasto C, Catalan R, Salamero M: Double blind study of imipramine versus phenelzine in melancholias and dysthymic disorders. Br J Psychiatry 1987; 151:639-642
49. Hellerstein DJ, Samstag LW, Cantillon M, Maurer M, Rosenthal J, Yanowitch P, Winston A: Follow-up assessment of medication-treated dysthymia. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20:427-442
50. Ravindran AV, Bialik RJ, Lapierre YD: Primary early onset dysthymia, biochemical correlates of the therapeutic response to fluoxetine, 1 : platelet monoamine oxidase and the dexamethasone suppression test. J Affect Disord 1994; 31: 111-117
51. Ravindran AV, Griffiths J, Waddell C, Anisman H: Stressful life events and coping styles in relation to dysthymia and major depressive disorder: variations associated with alleviation of symptoms following pharmacotherapy. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19:637-653
52. Baumhackl U, Biziere K, Fischbach R, Geretsegger C, Hebenstreit G, Radmayr E, Stabl M: Efficacy and tolerability of moclobemide compared with imipramine in depressive disorder (DSM-III): an Austrian double-blind multicentre study. Br J Psychiatry Suppl 1989; 6:78-83
53. Botte L, Evrard JL, Gilles C, Stenier P, Wolfrum C: Controlled comparison of RO 11-1163 (moclobemide) and placebo in the treatment of depression. Acta Psychiatr Belg 1992; 92:355-369
54. Duarte A, Mikkelsen H, Delini-Stula A: Moclobemide versus fluoxetine for double depression: a randomized double-blind study. J Psychiatr Res 1996; 30:453-458
55. Lecrubier Y, Guelfi JD: Efficacy of reversible inhibitors of monoamine oxidase-A in various forms of depression. Acta Psychiatr Scand 1990; 82:18-23
56. Versiani M, Amrein R, Stabl M: Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial. International Collaboration Study Group. Int Clin Psychopharmacol 1997; 12:183-193
57. Bakish D, Lapierre YD, Weinstein R, Klein J, Wiens A, Jones B, Horn E, Browne M, Bourget O, Blanchard A: Ritanserin, imipramine and placebo in the treatment of dysthymic disorder. J Clin Psychopharmacol 1993; 13:409-414
58. Bersani G, Pozzi F, Marini S, Grispini A, Pasini A, Ciani N: 5-HT2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin. Acta Psychiatr Scand 1991; 83:244-248
59. Ravindran A, Wiseman R: A double-blind, placebo-controlled study of sertraline in the treatment of outpatients with dysthymia, in 1997 Annual Meeting New Research Program and Abstracts. Washington, DC, American Psychiatric Association, 1997, p 191
60. Hollon SD, DeRubeis RJ: Placebo-psychotherapy combinations: inappropriate representations of psychotherapy in drug-psychotherapy comparative trials. Psychol Bull 1981; 90:467-477
61. Padesky CA, Greenberg D: Clinician's Guide to Mind Over Mood. New York, Guilford Press, 1995
62. Alford BA, Beck AT: Cognitive theory as an integrative theory for clinical practice, in The Integrative Power of Cognitive Therapy. New York, Guilford Press, 1997, pp 94-112
63. Rachman S: The evolution of cognitive behaviour therapy, in Science and Practice of Cognitive Behaviour Therapy. Edited by Clark DM, Fairburn CG. Oxford, UK, Oxford University Press, 1997, pp 3-26
64. Weissman MM: Psychotherapy in the maintenance treatment of depression. Br J Psychiatry 1994; 165:42-50
65. Fava GA, Grandi S, Zielezny M, Canestrari R, Morphy MA: Cognitive behavioral treatment of residual symptoms in primary major depressive disorder. Am J Psychiatry 1994; 151: 1295-1299
66. Blackburn IM, Moore RG: Controlled acute and follow up trial of cognitive therapy and pharmacotherapy in out-patients with recurrent depression. Br J Psychiatry 1997; 171:328-334
67. Walker V, Streiner DL, Novosel S, Rocchi A, Levine MAH, Dean DM: Health-related quality of life in patients with major depression who are treated with moclobemide. J Clin Psychopharmacol 1995; 15(Aug suppl 2):60S-67S
68. Wells KB, Stewart A, Hays RD, Burnam MA, Rogers W, Daniels M, Berry S, Greenfield S, Ware J: The functioning and well-being of depressed patients. JAMA 1989; 262:914-919
69. Friedman RA: Social impairment in dysthymia. Psychiatr Annals 1993; 23:632-637
70. Hellerstein DJ, Little SAS: Current perspectives on the diagnosis and treatment of double depression. CNS Drugs 1996; 5:344-357
71. Thase ME, Rush AJ: Treatment-resistant depression, in Psychopharmacology: The Fourth Generation of Progress. Edited by Bloom FE, Kupfer DJ. New York, Raven Press, 1995, pp 1081-1097
72. Ramana R, Paykel ES, Cooper Z, Hayhurst H, Saxty M, Surtees PG: Remission and relapse in major depression: a two-year prospective follow-up study. Psychol Med 1995; 25: 1161-1170
73. Fawcett J: Antidepressants: partial response in chronic depression. Br J Psychiatry Suppl 1994; 26:37-41
74. Kanfer FH: Motivation and emotion in behavior therapy, in Advances in Cognitive-Behavioral Therapy. Edited by Dobson KS, Craig KD. London, Sage Publications, 1996, pp 1-30
75. Sanderson WC: Cognitive behavior therapy. Am J Psychother 1997; 51:289-292